Biotech Stocks Flash Green: Clinical Catalysts and Earnings Fuel Healthcare Rally In Extended Session

Biotechnology and healthcare equities demonstrated impressive momentum during Wednesday’s after-hours trading window, with a cluster of positive developments propelling multiple names higher. Within the compressed timeframe—roughly 105 minutes into the extended session—investors had already rotated capital into names benefiting from trial readouts and forward guidance updates.

Clinical Data Breakthroughs Drive Oncology Sector Momentum

ALX Oncology Holdings Inc. (ALXO) emerged as the session’s standout performer, jumping 10.17% to land at $1.30 per share. The catalyst: the company unveiled promising Phase 2 investigator-sponsored trial data for evorpacept, its flagship therapeutic candidate. The combination regimen—evorpacept paired with rituximab and lenalidomide—demonstrated efficacy in treating indolent B-cell non-Hodgkin lymphoma patients. The full dataset will be presented at the American Society of Hematology (ASH) Annual Meeting 2025 scheduled for December 7 in Orlando, Florida.

Acrivon Therapeutics, Inc. (ACRV) similarly captured investor attention, rising 6.44% to $3.14 after signaling imminent clinical readouts. The company indicated it would release fresh efficacy data on ACR-368 and ACR-2316 on January 8, 2026, with an investor briefing slated for 8:30 a.m. ET—just 105 minutes after the formal press release drops at 7:30 a.m. ET.

Medical Device Maker Extends Winning Streak With Strong Quarterly Print

Globus Medical, Inc. (GMED) posted a more muted 9.34% advance to $99.00, though the underlying fundamentals proved compelling. The spinal-focused medtech firm reported fourth-quarter 2025 preliminary sales hitting approximately $823.2 million, translating to a robust 25.2% year-over-year expansion. Full-year revenue for 2025 is tracking toward $2.936 billion, a 16.5% uplift versus the prior-year baseline. The company’s 2026 outlook ranges between $3.18 billion and $3.22 billion in top-line revenue, with non-GAAP EPS guidance between $4.30 and $4.40 per share.

Mixed Signals in Broader Healthcare Complex

Several additional healthcare and biotech names registered gains without major headlines. RenovoRx, Inc. (RNXT) pushed 4.95% higher to $1.06, while Omeros Corp. (OMER) advanced 4.47% to $14.72. TherapeuticsMD, Inc. (TXMD) extended higher by 5.34% to $2.15, and Pyxis Oncology, Inc. (PYXS) climbed 4.93% to $1.49.

AnaptysBio, Inc. (ANAB) ticked upward 1.75% to $46.00 following confirmation that CEO Daniel Faga will participate in the 44th Annual J.P. Morgan Healthcare Conference slated for January 13, 2026—a marquee industry gathering that typically draws significant institutional participation.

EUDA Health Holdings Limited (EUDA) increased 3.73% to $2.50 after filing an amendment to its warrant agreement with Streeterville Capital, LLC. The Singapore-headquartered healthcare services provider operates integrated medical platforms across Singapore, Malaysia, and China, with a strategic emphasis on non-invasive procedural offerings.

The breadth of gainers across the biotech and medtech universe underscores sustained investor appetite for healthcare names ahead of the winter conference season and a fresh wave of clinical catalysts expected throughout early 2026.